Vesicular Gaba Transporter is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
<div class="infobox infobox-protein"> [@marty2002]
<table> [@schitine2022]
<tr><th colspan="2" style="background:#e8f4f8; text-align:center; font-size:1.1em;">Vesicular GABA Transporter</th></tr> [@wu2021]
<tr><td><strong>Protein Name</strong></td><td>Vesicular GABA Transporter (VGAT)</td></tr> [@gao2023]
<tr><td><strong>Gene</strong></td><td>[SLC32A1](/genes/slc32a1)</td></tr> [@bausch2020]
<tr><td><strong>UniProt ID</strong></td><td>[Q9Y3L3](https://www.uniprot.org/uniprot/Q9Y3L3)</td></tr> [@ichinohe2019]
<tr><td><strong>PDB ID</strong></td><td>5VIC</td></tr> [@liu2021]
<tr><td><strong>Molecular Weight</strong></td><td>55 kDa</td></tr>
<tr><td><strong>Subcellular Location</strong></td><td>Synaptic vesicle membrane</td></tr>
<tr><td><strong>Protein Family</strong></td><td>VGAT/SLC32 family</td></tr>
<tr><td><strong>Tissue Specificity</strong></td><td>Brain, spinal cord, retina</td></tr>
</table>
</div>
Vesicular Gaba Transporter is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
<div class="infobox infobox-protein"> [@marty2002]
<table> [@schitine2022]
<tr><th colspan="2" style="background:#e8f4f8; text-align:center; font-size:1.1em;">Vesicular GABA Transporter</th></tr> [@wu2021]
<tr><td><strong>Protein Name</strong></td><td>Vesicular GABA Transporter (VGAT)</td></tr> [@gao2023]
<tr><td><strong>Gene</strong></td><td>[SLC32A1](/genes/slc32a1)</td></tr> [@bausch2020]
<tr><td><strong>UniProt ID</strong></td><td>[Q9Y3L3](https://www.uniprot.org/uniprot/Q9Y3L3)</td></tr> [@ichinohe2019]
<tr><td><strong>PDB ID</strong></td><td>5VIC</td></tr> [@liu2021]
<tr><td><strong>Molecular Weight</strong></td><td>55 kDa</td></tr>
<tr><td><strong>Subcellular Location</strong></td><td>Synaptic vesicle membrane</td></tr>
<tr><td><strong>Protein Family</strong></td><td>VGAT/SLC32 family</td></tr>
<tr><td><strong>Tissue Specificity</strong></td><td>Brain, spinal cord, retina</td></tr>
</table>
</div>
The Vesicular GABA Transporter (VGAT), also known as SLC32A1 (Solute Carrier Family 32 Member 1), is a critical membrane protein responsible for transporting the inhibitory neurotransmitters GABA (gamma-aminobutyric acid) and glycine into synaptic vesicles. This transporter is essential for maintaining inhibitory neurotransmission throughout the central nervous system and plays a vital role in regulating neuronal excitability, synaptic transmission, and neural circuit function.
VGAT belongs to the major facilitator superfamily (MFS) of transporters and functions as a proton-coupled antiporter. The transporter uses the proton gradient established by the vacuolar-type H+-ATPase to drive the uptake of GABA and glycine into synaptic vesicles, ensuring these neurotransmitters are available for calcium-triggered release during synaptic transmission.
VGAT is a transmembrane protein consisting of 525 amino acids with 12 transmembrane helices arranged in the typical MFS transporter fold. The protein forms a barrel-like structure that creates a central pore for substrate translocation. Key structural features include:
VGAT operates as a proton-coupled symporter, using the energy from the proton gradient to transport GABA and glycine against their concentration gradients. The transport cycle involves:
VGAT exhibits broad substrate specificity, transporting both GABA and glycine with similar efficiency. This dual-transport capability is particularly important in mixed inhibitory synapses where both neurotransmitters may be co-released.
VGAT is expressed throughout the central nervous system with highest levels in:
VGAT is localized to the membrane of synaptic vesicles in GABAergic and glycinergic [neurons](/entities/neurons). The transporter is densely packed at the active zone of inhibitory synapses, where it ensures rapid replenishment of synaptic vesicles with neurotransmitters.
VGAT dysfunction is strongly associated with epileptic disorders. Loss-of-function mutations in SLC32A1 cause early-onset epilepsy and infantile spasms. The impaired GABA packaging leads to reduced inhibitory neurotransmission, neuronal hyperexcitability, and seizure generation. Mouse models with VGAT knockout exhibit severe spontaneous seizures and early mortality.
Alterations in VGAT expression and function have been reported in ALS. Studies show reduced VGAT in motor neurons of ALS patients and SOD1 transgenic mice. This reduction contributes to excitatory-inhibitory imbalance in motor circuits, potentially accelerating motor neuron degeneration. The loss of inhibitory control may exacerbate excitotoxicity, a key mechanism in ALS pathogenesis.
Evidence suggests VGAT is affected in Alzheimer's disease brain. Changes in GABAergic signaling contribute to network dysfunction and cognitive deficits. VGAT expression is altered in the hippocampus and cortex of AD patients, affecting inhibitory circuit function. Additionally, [Aβ](/proteins/amyloid-beta) pathology may directly impact GABAergic interneurons that express VGAT.
GABAergic dysfunction is a hallmark of Huntington's disease. Studies show reduced VGAT expression in the striatum and cortex of HD patients and mouse models. The loss of inhibitory signaling contributes to the characteristic hyperkinetic movements and cognitive deficits in HD. Restoring GABAergic function through VGAT modulation is being explored as a therapeutic strategy.
VGAT plays a role in PD pathophysiology, particularly in relation to levodopa-induced dyskinesias. Abnormal GABAergic signaling in the basal ganglia contributes to motor complications. VGAT expression and function are altered in PD models, affecting the balance between direct and indirect pathway signaling.
VGAT represents a promising therapeutic target for several neurological conditions:
Gene therapy strategies targeting VGAT include:
Pharmaceutical companies are developing VGAT modulators including:
SLC32A1 knockout mice exhibit:
Conditional knockout models have revealed region-specific roles:
VGAT as a biomarker target:
VGAT interacts with multiple neurodegenerative pathways:
The study of Vesicular Gaba Transporter has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.